WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a biopharmaceutical company focused on discovering and developing the first generation of nanoparticle-based vaccines and immunomodulatory drugs for the treatment and prevention of human diseases, announced today that Omid Farokhzad, M.D., co-founder and Vice Chair, has been named as a 2009 Mass High Tech All Star for his contributions to the life sciences industry.

LEXINGTON, Mass.--(BUSINESS WIRE)--TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, announced today the appointment of Julie Lekstrom Himes, M.D. to join TARIS in the position of Chief Medical Officer and Senior Vice President for Clinical Development. Dr. Himes has broad clinical research and operations experience within the biopharmaceutical industry, including Coley Pharmaceuticals and Millennium Pharmaceuticals. Prior to joining industry, Dr.

Concert Earns $12 Million Milestone from GlaxoSmithKline

CTP-518 has Potential as Unboosted HIV Protease Inhibitor

BIO Pacific Rim Summit – Honolulu, HI – November 9, 2009 – Joule Biotechnologies, Inc. today announced a major step forward in its development of renewable fuels, achieving direct microbial conversion of carbon dioxide (CO2) into hydrocarbons via engineered organisms, powered by solar energy.

Announces Near-Term System and Diagnostics Initiatives

Extends VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Expanded Readouts of Key Protease Biomarkers in Research and Drug Development

ABBOTT PARK, Ill. and WALTHAM, MA., November 17, 2009 — Abbott (NYSE: ABT) and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott’s Architect immunochemistry instrument platform, specifically the company’s i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine’s intellectual property related to galectin-3. Financial terms were not disclosed.

Experienced Drug Hunters Armed with Structure-Based G Protein-Coupled Receptor (GPCR) Drug Discovery Technology From The Scripps Research Institute

Expands VisEn’s Fluorescence Molecular Imaging Agent Portfolio to Enable Enhanced Multiplexed Readouts of Key Biomarkers in Research and Drug Development

Company Discovers Novel Mechanism to Increase Red Blood Cells

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 8, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.